Topline results of Phase 3 studies of simufilam for Alzheimer's...
Feb 8, 2024 · Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease.. Top-line results from the RETHINK-ALZ trial (NCT04994483) are expected by the end of this year, according to simufilam’s developer Cassava Sciences.Results from the second study, REFOCUS-ALZ study (NCT05026177), are ...
Alzheimer’s blood test gets FDA breakthrough device designation
Mar 14, 2024 · by Margarida Maia, PhD March 14, 2024. The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Quanterix ’s experimental blood test measuring p-Tau 217, the protein that builds up as toxic tangles in the brains of people with Alzheimer’s disease. The test, Simoa p-Tau 217, has the potential to help doctors ...
Aricept (Donepezil) - Alzheimer's News Today
Aricept (donepezil) is an oral medication used to treat the symptoms of dementia caused by Alzheimer’s disease (AD). It is marketed by Eisai in collaboration with Pfizer.. How Aricept works. Aricept is part of a class of drugs called “cholinesterase inhibitors.” It is a reversible inhibitor of an enzyme — a catalyst that can trigger a chemical reaction — called acetylcholinesterase.
Neurostimulation Device for Alzheimers Granted FDA …
Jan 25, 2021 · Non-invasive Neurostimulation Device Wins FDA’s Breakthrough Status. by Patricia Inacio, PhD January 25, 2021. Cognito Therapeutic ’s neurostimulation device — a next-generation digital therapeutic designed to treat memory and cognition symptoms in Alzheimer’s disease — has been granted a breakthrough device designation by the U.S ...
Some Dementias Are Reversible, Making a Proper Diagnosis Crucial
Nov 22, 2021 · An early diagnosis could help keep the disease from progressing very quickly. However, diagnosis by a competent health professional is equally imperative for a person who is experiencing dementia symptoms unrelated to Alzheimer’s. Their symptoms could be reversed if the diagnosis points to something other than Alzheimer’s disease.
CogniCann, Potential Alzheimer's Cannabinoid, Being Prepared for...
Apr 19, 2022 · by Lindsey Shapiro, PhD April 19, 2022. Sciensus Rare, a Dutch healthcare group, was given rights to distribute CogniCann, MGC Pharmaceutical’s cannabinoid-based investigative treatment for people with dementia and Alzheimer’s disease in Europe, should it be approved for commercial use or use in select early access programs. The agreement ...
1st Alzheimer's Patient Given Bryostatin in Dose-finding Trial
Jul 25, 2022 · According to the therapy’s developer, Synaptogenix — previously called Neurotrope — the dose-finding trial will prepare the company to move forward with bryostatin’s next phase of clinical development. The therapy is designed to improve cognitive function in people with moderate to severe Alzheimer’s.
Biomarker test to diagnose Alzheimer's wins FDA breakthrough...
May 2, 2024 · The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Phospho-Tau 217 (pTau217), a blood-based biomarker test that can help distinguish Alzheimer’s disease from other neurodegenerative disorders. The test, developed by Roche in collaboration with Eli Lilly, is intended to support a more accurate ...
Latest Data on Alzheimer's Drug Namenda Confirms Beneficial …
by Alice Melão April 24, 2017. Results from four recent studies confirmed the beneficial clinical effects of Namenda (memantine), an FDA-approved Alzheimer’s therapy, to treat the disease’s behavioral and functional symptoms in people with moderate to severe disease. The studies, sponsored by Allergan, are being presented in poster format ...
Simufilam found safe in review of ongoing Alzheimer’s clinical trials
by Andrea Lobo September 26, 2024. After completing a third review of interim safety data, an independent safety monitoring board has recommended the continuation — without modifications — of two ongoing Phase 3 clinical trials testing the oral therapy simufilam in people with Alzheimer’s disease. The board’s findings were announced by ...